Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

Affiliations

• ¹ Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilans University Munich, Munich, Germany [email protected].
• ² Praxiszentrum St. Bonifatius, Munich, Germany.
• ³ Department of Rheumatology, Clinical Immunology and Osteology, München Klinik Bogenhausen, Munich, Germany.
• ⁴ Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Giessen, Germany.
• ⁵ Division of Rheumatology and Clinical Immunology, Deparmtent of Medicine IV, Ludwig Maximilians University Munich, Munich, Germany.